Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.

Noriaki Kawano, Nobuyuki Ono, Shuro Yoshida, Takuro Kuriyama, Kiyoshi Yamashita, Kiichiro Beppu, Yoshiya Shimao, Kosuke Marutsuka, Yuji Ueda, Akira Ueda

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    Immunodeficiency-associated lymphoproliferative disorders (LPD) in rheumatoid arthritis are a rare, aggressive, and life-threatening clinical entity. We describe a 60-year-old man who had rheumatoid arthritis that was treated with methotrexate. Eight months after the treatment, the case was diagnosed as Epstein-Barr virus-negative LPD (diffuse large B-cell lymphoma) with abdominal bulky mass and clinical stage IVB at high risk in the international prognostic index. Immediate withdrawal of methotrexate led the patient to achieve complete remission, and 8 subsequent courses of rituximab treatment for the prevention of relapse kept the patient disease-free for 29 months. Our case suggests that these treatments may be an effective, safe, and feasible strategy for immunodeficiency-associated LPD in rheumatoid arthritis.

    Original languageEnglish
    Pages (from-to)193-198
    Number of pages6
    JournalJournal of clinical and experimental hematopathology : JCEH
    Volume52
    Issue number3
    DOIs
    Publication statusPublished - Jan 1 2012

    Fingerprint

    Lymphoproliferative Disorders
    Secondary Prevention
    Human Herpesvirus 4
    Methotrexate
    Rheumatoid Arthritis
    Lymphoma, Large B-Cell, Diffuse
    Therapeutics
    Rituximab

    All Science Journal Classification (ASJC) codes

    • Medicine(all)

    Cite this

    Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration. / Kawano, Noriaki; Ono, Nobuyuki; Yoshida, Shuro; Kuriyama, Takuro; Yamashita, Kiyoshi; Beppu, Kiichiro; Shimao, Yoshiya; Marutsuka, Kosuke; Ueda, Yuji; Ueda, Akira.

    In: Journal of clinical and experimental hematopathology : JCEH, Vol. 52, No. 3, 01.01.2012, p. 193-198.

    Research output: Contribution to journalArticle

    Kawano, Noriaki ; Ono, Nobuyuki ; Yoshida, Shuro ; Kuriyama, Takuro ; Yamashita, Kiyoshi ; Beppu, Kiichiro ; Shimao, Yoshiya ; Marutsuka, Kosuke ; Ueda, Yuji ; Ueda, Akira. / Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration. In: Journal of clinical and experimental hematopathology : JCEH. 2012 ; Vol. 52, No. 3. pp. 193-198.
    @article{95935399db8442a98dbe016f1ea6ba6d,
    title = "Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.",
    abstract = "Immunodeficiency-associated lymphoproliferative disorders (LPD) in rheumatoid arthritis are a rare, aggressive, and life-threatening clinical entity. We describe a 60-year-old man who had rheumatoid arthritis that was treated with methotrexate. Eight months after the treatment, the case was diagnosed as Epstein-Barr virus-negative LPD (diffuse large B-cell lymphoma) with abdominal bulky mass and clinical stage IVB at high risk in the international prognostic index. Immediate withdrawal of methotrexate led the patient to achieve complete remission, and 8 subsequent courses of rituximab treatment for the prevention of relapse kept the patient disease-free for 29 months. Our case suggests that these treatments may be an effective, safe, and feasible strategy for immunodeficiency-associated LPD in rheumatoid arthritis.",
    author = "Noriaki Kawano and Nobuyuki Ono and Shuro Yoshida and Takuro Kuriyama and Kiyoshi Yamashita and Kiichiro Beppu and Yoshiya Shimao and Kosuke Marutsuka and Yuji Ueda and Akira Ueda",
    year = "2012",
    month = "1",
    day = "1",
    doi = "10.3960/jslrt.52.193",
    language = "English",
    volume = "52",
    pages = "193--198",
    journal = "Journal of clinical and experimental hematopathology : JCEH",
    issn = "1346-4280",
    publisher = "Nihon Rinpa Monaikei Gakkai",
    number = "3",

    }

    TY - JOUR

    T1 - Successful treatment of immunodeficiency-associated EBV-negative lymphoproliferative disorders in rheumatoid arthritis by methotrexate withdrawal and prevention of its relapse by rituximab administration.

    AU - Kawano, Noriaki

    AU - Ono, Nobuyuki

    AU - Yoshida, Shuro

    AU - Kuriyama, Takuro

    AU - Yamashita, Kiyoshi

    AU - Beppu, Kiichiro

    AU - Shimao, Yoshiya

    AU - Marutsuka, Kosuke

    AU - Ueda, Yuji

    AU - Ueda, Akira

    PY - 2012/1/1

    Y1 - 2012/1/1

    N2 - Immunodeficiency-associated lymphoproliferative disorders (LPD) in rheumatoid arthritis are a rare, aggressive, and life-threatening clinical entity. We describe a 60-year-old man who had rheumatoid arthritis that was treated with methotrexate. Eight months after the treatment, the case was diagnosed as Epstein-Barr virus-negative LPD (diffuse large B-cell lymphoma) with abdominal bulky mass and clinical stage IVB at high risk in the international prognostic index. Immediate withdrawal of methotrexate led the patient to achieve complete remission, and 8 subsequent courses of rituximab treatment for the prevention of relapse kept the patient disease-free for 29 months. Our case suggests that these treatments may be an effective, safe, and feasible strategy for immunodeficiency-associated LPD in rheumatoid arthritis.

    AB - Immunodeficiency-associated lymphoproliferative disorders (LPD) in rheumatoid arthritis are a rare, aggressive, and life-threatening clinical entity. We describe a 60-year-old man who had rheumatoid arthritis that was treated with methotrexate. Eight months after the treatment, the case was diagnosed as Epstein-Barr virus-negative LPD (diffuse large B-cell lymphoma) with abdominal bulky mass and clinical stage IVB at high risk in the international prognostic index. Immediate withdrawal of methotrexate led the patient to achieve complete remission, and 8 subsequent courses of rituximab treatment for the prevention of relapse kept the patient disease-free for 29 months. Our case suggests that these treatments may be an effective, safe, and feasible strategy for immunodeficiency-associated LPD in rheumatoid arthritis.

    UR - http://www.scopus.com/inward/record.url?scp=84878387209&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84878387209&partnerID=8YFLogxK

    U2 - 10.3960/jslrt.52.193

    DO - 10.3960/jslrt.52.193

    M3 - Article

    C2 - 23269079

    AN - SCOPUS:84878387209

    VL - 52

    SP - 193

    EP - 198

    JO - Journal of clinical and experimental hematopathology : JCEH

    JF - Journal of clinical and experimental hematopathology : JCEH

    SN - 1346-4280

    IS - 3

    ER -